We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
+20.24%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$216M
AUM Growth
-$32M
Cap. Flow
-$45.1M
Cap. Flow %
-20.9%
Top 10 Hldgs %
70.66%
Holding
99
New
11
Increased
15
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$2.87M
2
ALKS icon
Alkermes
ALKS
+$2.27M
3
MRSN
Mersana Therapeutics
MRSN
+$2.12M
4
TGTX icon
TG Therapeutics
TGTX
+$1.47M
5
BHVN icon
Biohaven
BHVN
+$1.37M

Top Sells

Rank Stock Value
1
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$17.4M
2
CLMT icon
Calumet Specialty Products
CLMT
+$11.7M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.96M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$5.54M
5
VRNA
Verona Pharma
VRNA
+$4.09M

Sector Composition

Rank Sector Weight
1 Healthcare 41.34%
2 Materials 20.5%
3 Financials 18.92%
4 Communication Services 13.33%
5 Miscellaneous 3.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLMT icon
1
Calumet Specialty Products
CLMT
$4.74B
$44M 20.38%
2,214,969
-610,262
-22% -$11.7M
APO icon
2
Apollo Global Management
APO
$77.8B
$32.6M 15.08%
225,000
– –
GOOG icon
3
Alphabet (Google) Class C
GOOG
$4.1T
$28.7M 13.28%
91,420
-20,800
-19% -$5.96M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.78B
$8.72M 4.04%
415,000
-13,000
-3% -$227K
XERS icon
5
Xeris Biopharma Holdings
XERS
$1.55B
$7.61M 3.53%
970,000
-45,000
-4% -$354K
TVTX icon
6
Travere Therapeutics
TVTX
$6.23B
$7.11M 3.29%
186,000
-74,000
-28% -$2.41M
BBIO icon
7
BridgeBio Pharma
BBIO
$14.6B
$6.5M 3.01%
85,000
– –
PTGX icon
8
Protagonist Therapeutics
PTGX
$9.44B
$6.38M 2.95%
73,000
-10,000
-12% -$818K
JPM icon
9
JPMorgan Chase
JPM
$940B
$6.28M 2.91%
19,477
-897
-4% -$278K
JAAA icon
10
Janus Henderson AAA CLO ETF
JAAA
$30.4B
$4.73M 2.19%
93,528
-344,226
-79% -$17.4M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.62B
$4.51M 2.09%
145,000
+28,426
+24% +$780K
CPRX
12
DELISTED
Catalyst Pharmaceutical
CPRX
$4.41M 2.04%
189,000
– –
COGT icon
13
Cogent Biosciences
COGT
$6.12B
$3.62M 1.68%
+102,000
New +$2.87M
RCUS icon
14
Arcus Biosciences
RCUS
$3.7B
$2.89M 1.34%
121,241
+26,041
+27% +$531K
ALKS icon
15
Alkermes
ALKS
$7.63B
$2.66M 1.23%
95,000
+75,700
+392% +$2.27M
DCGO icon
16
DocGo
DCGO
$38.4M
$2.34M 1.09%
2,670,850
-400,000
-13% -$427K
HELP
17
Cybin Inc
HELP
$905M
$2.33M 1.08%
285,182
+144,940
+103% +$933K
CYTK icon
18
Cytokinetics
CYTK
$10.5B
$2.16M 1%
34,000
+4,000
+13% +$249K
ATRC icon
19
AtriCure
ATRC
$2.73B
$2.03M 0.94%
51,400
+3,400
+7% +$125K
AB icon
20
AllianceBernstein
AB
$3.42B
$1.85M 0.86%
48,000
– –
ACLX
21
DELISTED
Arcellx
ACLX
$1.68M 0.78%
25,700
– –
XBI icon
22
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$1.59M 0.73%
13,000
+8,000
+160% +$917K
TECX
23
Tectonic Therapeutic
TECX
$594M
$1.54M 0.71%
74,000
– –
WVE icon
24
Wave Life Sciences
WVE
$968M
$1.53M 0.71%
90,000
– –
JNJ icon
25
Johnson & Johnson
JNJ
$649B
$1.43M 0.66%
6,922
– –
1
2 3 4

Similar funds

GFL
Granite FO LLC Bedford, New Hampshire $189M AUM 56.18% 1-Year Est. Return
SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FSBI
Fearless Solutions (Best Invest) San Antonio, Texas $189M AUM 32.69% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM

David M. Knott Jr's Q4 2025 Portfolio in Review

As of Q4 2025, David M. Knott Jr held 99 positions worth $216M, down 13% from $248M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

David M. Knott Jr withdrew a net $45.1M in Q4 2025, closing 12 positions and reducing 20 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $5.54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 35% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in Cogent Biosciences worth $3.62M.

  • David M. Knott Jr's largest Q4 2025 buy was Cogent Biosciences: 102,000 shares worth $3.62M.
  • David M. Knott Jr added most to Alkermes in Q4 2025, an estimated $2.27M increase.
  • David M. Knott Jr's biggest Q4 2025 reduction was Janus Henderson AAA CLO ETF, cutting an estimated $17.4M.
  • David M. Knott Jr fully exited Avadel Pharmaceuticals in Q4 2025, selling an estimated $5.54M.
  • David M. Knott Jr's ten largest holdings make up 71% of its $216M portfolio in Q4 2025.
  • David M. Knott Jr opened 11 new positions and closed 12 in Q4 2025.
  • David M. Knott Jr's portfolio value fell 13% quarter-over-quarter to $216M.

Based on David M. Knott Jr's 13F filing for Q4 2025, filed 12 Feb 2026.